{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-041524","form_type":"8-K","ticker":"BIAF","cik":"0001712762","company_name":"bioAffinity Technologies, Inc.","filed_at":"2023-11-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.147659+00:00","generated_at":"2026-06-08T02:34:47.134232+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"bioAffinity Q3 revenue surges to $298K on PPLS acquisition; net loss narrows to $2.3M","bullets":["Revenue of $298,484 for Q3 2023, up from $1,150 in prior year, primarily from acquired PPLS lab.","Net loss of $2.3M ($0.26 per share) vs $4.9M ($1.17) in prior year; cash at $4.5M down from $11.4M.","Acquired non-medical assets of Village Oaks Pathology Services on Sept 18, 2023; PPLS forecast to contribute $8.7M net revenue over next 12 months.","CMS issued preliminary payment decision for CyPath Lung; final expected Nov 2023 with effective date Jan 1, 2024.","Revenue outlook for full year 2023: $2.1-$2.3M; next 12 months: $8.4-$9.0M."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-041524","json":"https://secwatch.observer/filing/0001493152-23-041524.json","markdown":"https://secwatch.observer/filing/0001493152-23-041524.md","text":"https://secwatch.observer/filing/0001493152-23-041524.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1712762/000149315223041524/0001493152-23-041524-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1712762/000149315223041524/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T02:34:47.134232+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a081ff069e60963a5e12c1b770a7a1d4b9797cb1","claim":"bioAffinity Technologies, Inc. reported financial results for quarter ended September 30, 2023.","evidence_excerpt":"On November 14, 2023, bioAffinity Technologies, Inc., a Delaware corporation (the \"Registrant\"), issued a press release that included financial information for its quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1712762/000149315223041524/0001493152-23-041524-index.htm","confidence":0.4,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"b5a6e7ffa19c4722204d7b84bceada04217a27f9","claim":"bioAffinity Technologies, Inc. reported three and nine months ended Sept. 30, 2023 results: revenue $298,484, EPS $0.26 per share. Guidance reaffirmed.","evidence_excerpt":"with larger medical systems, we anticipate substantial revenue growth for CyPath ® Lung.” Third Quarter Financial Results Revenue for the third quarter of 2023 increased to $298,484, up from $1,150 in the prior-year period. Prior to the Sept. 18, 2023, acquisition of PPLS, bioAffinity Technologies’ revenue was generated from royalties from sales of CyPath ®","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1712762/000149315223041524/0001493152-23-041524-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and nine months ended Sept. 30, 2023"},{"label":"Revenue","value":"$298,484"},{"label":"EPS","value":"$0.26 per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}